Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_000277.1(PAH):c.898G>T (p.Ala300Ser)

Curation Version - 1.0
Curation History
JSON LD for Version 1.0

CA273108

92751 (ClinVar)

Gene: PAH

Condition: phenylketonuria

Inheritance Mode: Autosomal recessive inheritance

Link to MONDO

UUID: 1cd06d79-1c2c-4338-936e-15faf0063222

Approved on: 2018-08-10

Published on: 2019-04-05

HGVS expressions

NM_000277.1:c.898G>T

NM_000277.1(PAH):c.898G>T (p.Ala300Ser)

NC_000012.12:g.102851701C>A

CM000674.2:g.102851701C>A

NC_000012.11:g.103245479C>A

CM000674.1:g.103245479C>A

NC_000012.10:g.101769609C>A

NG_008690.1:g.70902G>T

NG_008690.2:g.111710G>T

NM_000277.2:c.898G>T

NM_001354304.1:c.898G>T

NM_000277.3:c.898G>T

ENST00000307000.7:c.883G>T

ENST00000549247.6:n.657G>T

ENST00000551114.2:n.560G>T

ENST00000553106.5:c.898G>T

ENST00000635477.1:n.59G>T

Pathogenic

PP4_Moderate PS3 PM3_Very Strong PP3

PM2 PM5

Evidence Links 2

Expert Panel

Phenylketonuria VCEP

Criteria Specification Information

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Phenylketonuria VCEP

PAH-specific ACMG/AMP criteria applied: PP3: Deleterious in SIFT, Polyphen2, MutationTaster; PP4_Moderate: A300S found on 56/588 hyperphenylalaninemic patients, BH4 deficiency excluded. Upgraded per ClinGen Metabolic WG. (PMID:21147011); PM3_VeryStrong: Detected with c.1066-11G>A (P), R261Q(P/LP), L48S (P), R176X (P) in 20 patients. (PMID:21147011); PS3: A300S in vitro PAH activity of 31% (PMID:17935162). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PP4_Moderate, PM3_VeryStrong, PS3).

PP4_Moderate

A300S found on 56/588 hyperphenylalaninemic patients, BH4 deficiency excluded. Upgraded per ClinGen Metabolic WG.

A total of 588 hyperphenylalaninemic patients were investigated. Assessment of the PAH gene and genes of the BH4 synthesis/ recycling pathways (PTS and QDPR). A300S found on 56 alleles. PubMed:21147011

PS3

A300S in vitro PAH activity of 31%

A300S has average residual PAH activity of 31%. PubMed:17935162

PM3_Very Strong

Detected with c.1066-11G>A (P), R261Q(P/LP), L48S (P), R176X (P) in 20 patients.

A300S in trans with c.1066-11G>A (VarID 607, Pathogenic in ClinVar) in 10 patients. Homozygous in 9 patients. Detected with p.R261Q in 6 patients. With IVS7+4A>G in 2 patients. with p.L48S in 2 patients. with p.R176X in 2 patients. with 8 other mutations in 8 patients. PubMed:21147011

PP3

Deleterious in SIFT, Polyphen2, MutationTaster

PM2

MAF in gnomAD: 0.00661

PM5

No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

Curation History

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.